Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
David Cohn MD
To estimate the progression-free survival hazard ratio of the combinationof weekly paclitaxel with Reolysin® to weekly paclitaxel alone in patientswith persistent or recurrent ovarian, fallopian tube, or primary peritonealcancer.
To determine the frequency and severity of adverse events associated withtreatment with weekly paclitaxel alone and weekly paclitaxel withREOLYSIN® as assessed by CTCAE.
Patients with persistent or recurrent ovarian, fallopian tube, or primary peritonealcancer.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.